Phase 2RecruitingPriority 3 · Moderate priorityNCT06733051
Phase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50)
Plain-language summary
This trial is testing Golidocitinib for patients with extranodal NK/T-cell lymphoma (ENKTL) whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. This trial does not currently have sites in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Age 18 Years or older
- Lymphoma came back or did not respond to prior treatment
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Golidocitinib (DRUG): 150 mg, administered once daily from Day 1 to Day 21 (D1-D21) | Benmelstobart (DRUG): 1200 mg, administered on Day 1 (D1) of every cycle
Golidocitinib, Benmelstobart
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details